Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company at the forefront of developing targeted therapies for metastatic diseases, has announced its financial results for the second quarter of 2025. The company reported a net loss of $5.7 million, or $1.99 per share, a notable improvement from the $7.4 million, or $16.75 per share, loss recorded in the same quarter the previous year. This financial update comes alongside significant advancements in the company's research and development efforts, particularly in the field of immuno-oncology.
Research and development expenses for Q2 2025 were reported at $2.6 million, up from $2.2 million in Q2 2024, reflecting the company's increased investment in its proprietary technologies and therapies. General and administrative expenses saw a decrease to $3.1 million from $3.6 million, indicating a more streamlined operational approach. Calidi Biotherapeutics concluded the quarter with $5.3 million in cash and $0.1 million in restricted cash, positioning the company for continued research and development activities.
Among the quarter's highlights was the release of new preclinical data on CLD-401, part of the company's RedTail platform. This data demonstrated enhanced efficacy through the systemic delivery of an IL15 superagonist and immune-evasion via engineered CD55 expression, marking a significant step forward in the treatment of metastatic diseases. Additionally, Calidi Biotherapeutics successfully raised $4.6 million through a warrant inducement offering, bringing the total gross proceeds for 2025 to $15.7 million. This financial boost supports the company's ongoing and future clinical trials.
A pivotal achievement for Calidi Biotherapeutics in Q2 2025 was receiving FDA Fast Track Designation for CLD-201, its therapy targeting soft tissue sarcoma. This designation accelerates the development and review of drugs intended to treat serious conditions and fill unmet medical needs, underscoring the potential of CLD-201 to make a meaningful impact in cancer treatment. The company has also opened an Investigational New Drug (IND) application for a Phase 1 trial of CLD-201, further advancing its clinical pipeline.
For more detailed information on Calidi Biotherapeutics' Q2 2025 results and business highlights, visit https://ibn.fm/K3CfE. The company's progress in developing targeted therapies for metastatic diseases represents a beacon of hope for patients worldwide, offering the potential for more effective treatments against some of the most challenging cancers.
